Evidence map›Paper›PMID 32913542›Full record

ArticleAmerican journal of translational research2020

MiR-422a in gastric cancer cells directly targets CDC40 and modulates cell proliferation.

Fanglai Zhu, Hao Li, Fei Ding, Hao Guo, Hong Mou, Jie Ma

Open access · greenAbstract read
In one paragraph

Article in American journal of translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Fanglai ZhuDepartment of Gastroenterology, The First People's Hospital of Anqing Anqing, Anhui, China.
Hao LiDepartment of Gastroenterology, The First People's Hospital of Anqing Anqing, Anhui, China.
Fei DingDepartment of Gastroenterology, The First People's Hospital of Anqing Anqing, Anhui, China.
Hao GuoDepartment of Gastroenterology, The First People's Hospital of Anqing Anqing, Anhui, China.
Hong MouDepartment of Pathology, Zhejiang Provincial People's Hospital, Hangzhou Medical College Hangzhou, Zhejiang, China.
Jie MaDepartment of Pathology, Zhejiang Provincial People's Hospital, Hangzhou Medical College Hangzhou, Zhejiang, China.
Anqing City Hospital · CNHangzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs have been shown to be involved in a variety of different human cancers, including gastric cancer, functioning as post-transcriptional regulators of oncogenes or tumor suppressors. This study aimed to clarify the role of miR-422a in gastric cancer and further elucidate the pathogenesis thereof. To this end, miR-422a expression was initially determined in gastric cancer tissues and cells. Our results showed decreased miR-422a and increased cell division cycle 40 (CDC40) expression in gastric cancer. Dual-luciferase reporter assay further confirmed that miR-422a targeted CDC40. Altogether, this study showed that miR-422a downregulated CDC40, thereby affecting cell cycle progression. Moreover, restoration of miR-422a inhibited gastric cancer cell proliferation. In summary, this study has been the first to show that miR-422a was associated with CDC40 levels in human gastric cancer cells and that disease development may be attributed to CDC40.

Indexed as

CDC40gastric cancermiR-422aproliferation

Identifiers

PMID32913542
PMCPMC7476107
OpenAlexW3084569470

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.